↑ Rising
Business
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
Roche has entered a $1.53 billion exclusive global licensing agreement with Simcere for the B-cell-targeting antibody SIM0660.
1 trends tracked about this subject — the full history, oldest to newest below.
Roche has entered a $1.53 billion exclusive global licensing agreement with Simcere for the B-cell-targeting antibody SIM0660.